Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals (LGND) is a US-based biotechnology company that provides technologies and services to help other drug developers discover, develop and commercialise medicines. Instead of focusing mainly on its own drug pipeline, Ligand earns revenue through licensing, milestone payments, royalties and strategic collaborations tied to partner programmes. Its portfolio includes platform technologies such as Captisol (drug formulation) and OmniAb (antibody discovery), which can broaden the company’s exposure across therapeutic areas. With a market capitalisation of about $3.66 billion, Ligand offers a royalty-driven business model that can deliver recurring revenues, but it remains dependent on partner success, regulatory approvals and licensing activity. Investors should be aware that biotech stocks are typically volatile; past performance does not predict future returns. This is general, educational information and not personal investment advice — suitability depends on your circumstances and risk tolerance, so consider professional advice before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ligand Pharmaceuticals' stock with a target price of $133.43, indicating potential growth.
Financial Health
Ligand Pharmaceuticals is earning strong profits and generating good cash flow, showing solid financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LGND
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Royalty Revenue Model
Recurring royalties and milestone payments can provide revenue visibility, though those streams depend on partner successes and are vulnerable to setbacks.
Proprietary Technology Platforms
Platforms such as Captisol and OmniAb can attract partners and diversify exposure, but they require ongoing investment and commercial uptake to deliver value.
Extensive Partnership Exposure
A wide partner base spreads risk across programmes and indications, yet regulatory delays or clinical failures at partners can still materially affect results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
